Maspin is a member of the serpin family of protease inhibitors. It is a 42 kDa cytoplasmic protein that is reported to have tumour suppressor activity. The loss of maspin gene expression is correlated with increased invasiveness and the risk of metastases in breast cancer. We studied maspin expression in primary melanoma lesions obtained from 76 patients. Immunostaining of 5 µm sections for maspin expression was obtained using the citrate antigen retrieval method. The extent of immunostaining was scored by recording the proportion of immunoreactive cells and the intensity of immunostaining. Our results demonstrated that maspin expression was downregulated in intermediate thickness and thick melanoma lesions compared with thin lesions. These results suggest that loss of maspin expression might play a role in melanoma progression, invasion and metastatic dissemination. Further studies are needed to clarify the clinicopathological significance of maspin expression in melanoma.
Introduction
The maspin gene is a serpin (serine protease inhibitor)-coding gene, which was originally reported to act as a tumour suppressor gene in breast and prostatic cancers. 1 -3 The maspin gene has been localized to chromosome 18q21.3-3-q23, within the same region that contains plasminogen activator inhibitor 2 (PAI-2) and Bcl-2. It has been isolated from normal mammary epithelial cells by subtractive hybridization and it is thought to play a role in blocking cancer progression, i.e. motility, invasiveness in vitro and the metastatic process in vivo. 1 The 42 kDa gene product of the maspin gene shares sequence homology with different members of the serpin family, including PAI-1 and PAI-2. The biological functions and regulatory mechanisms of maspin (mammary serpin) remain poorly understood, but maspin may inhibit angiogenesis and can interact with the p53 tumour suppressor pathway. 2, 3 These observations indicate that different biological mechanisms may be activated by maspin in order for it to act as a tumour suppressor gene product. 4 Investigative reports provide clinical evidence that maspin expression is inversely correlated with the American Joint Committee on Cancer (AJCC) stage of breast, prostate and oral cancers. 3,5 -10 Loss of maspin gene expression has been shown to lead to increased invasiveness and migration properties both in vitro and in vivo. 11 -13 In breast tissue, maspin can be detected in the normal myoepithelial cells, which surround mammary ductal epithelium. Downregulation of maspin expression has been demonstrated in breast cancers. The maspin-expressing normal cells may protect against the progression of ductal carcinoma in situ to invasive breast carcinoma. 14 -17 Transfection of the breast carcinoma cell line MDA-MB-435 with maspin cDNA significantly inhibits local and metastatic tumour growth in nude mice. In addition, recombinant maspin reduces cell motility of breast and prostate cancer cells.
Surprisingly, maspin seems to behave as an oncogene and not as a tumour suppressor gene in pancreatic and ovarian cancers; maspin upregulation and intense cytoplasmic maspin immunoreactivity have been demonstrated in cases with poor prognosis. 18, 19 Recently, Wada et al. 20 showed that maspin expression could be repressed in normal skin melanocytes and melanocytic naevi in a cell type-specific manner. In the present study, we aimed to characterize maspin expression in a large series of primary melanoma lesions, in benign naevi and melanoma metastases using immunohistochemistry.
Materials and methods

SAMPLE SELECTION
The present investigation included: 76 randomly selected primary melanoma lesions taken from a series of 76 patients (39 men and 37 women (mean age, 51.6 years; age range, 19 -83 years); 10 randomly selected melanoma metastases (skin, liver, lymph node); and 13 randomly selected benign naevi (mixed lesions including junctional naevi, compound naevi and intradermal naevi) that were used as a control group. This study was conducted in accordance with local Ethics Committee guidelines and patient consent was obtained.
Two independent observers reviewed the lesions and checked the diagnoses. The Breslow index was used for all malignant melanomas and two groups of lesions were defined: the first group, thin primary lesions (n = 24), included AJCC/UICC 2002 pT1 tumours (thin thickness lesions, Breslow index ≤ 1 mm); and the second group, intermediate thickness and thick primary lesions (n = 52), included AJCC/UICC pT2, 3 and 4 tumours. 21 Two slides of tissue sections (thickness, 5 µm) were obtained from each biopsy specimen and fixed with 10% phosphate-buffered formalin.
IMMUNOCHEMISTRY METHODS
The tissue sections were prepared for immunochemistry by removing the paraffin. Primary antibody (mouse monoclonal antihuman maspin antibody, Becton Dickinson 550839, clone G167-70 [dilution 1/20; Becton Dickinson Pharmingen, San Diego, CA, USA]) was incubated for 60 min at room temperature after using the citrate buffer and high-temperature unmasking technique. Immunostaining with a secondary antibody was performed using a Klinipath kit DPVB-110 HRP (ImmunoLogic, Duiven, The Netherlands) with AEC+ substratechromogen (3-amino-9-ethylcarbazole containing hydrogen peroxide, stabilizers, enhancers and antimicrobial agents Dako K3469 [Dako Corporation, Carpinteria, USA]). The slides were counterstained using 
The extent of immunohistochemical staining was estimated by determining a global score, which was calculated by adding the proportion and intensity scores together to produce a total (Σ). 22 haematoxylin (Dako S2020). A haematoxylin-stained histological control slide, which was not exposed to primary antibody, was obtained for each specimen to act as a negative control.
The extent of immunostaining was recorded by measuring the proportion of immunoreactive cells and their staining intensity, as described previously. 22 The proportion of immunoreactive cells was recorded as follows: 0, no immunoreactive cells; 1, ≤ 10% of cells were stained; 2, 11 -50% of cells were stained; 3, > 50% of cells were stained. The intensity score was graded as follows: 0, no immunoreactivity; 1, weak staining; 2, intermediate staining; 3, strong staining. The extent of immunohistochemical staining was estimated by determining a global score, which was calculated by adding the proportion and intensity scores together to produce a total (Σ), and this was assigned as follows: negative, Σ = 0/1; positive, Σ = 2 -4; stronger positive, Σ = 5/6.
STATISTICAL ANALYSIS
Differences in maspin expression were analysed using the χ 2 test and the Fisher's exact test for small numbers. P-values < 0.05 were considered statistically significant.
Results
As described previously by Reis-Filho et al., 23 we found keratinocytes stained strongly positive for maspin and they were used as a positive control for the histological slides. The level of expression of maspin in thin (AJCC/UICC pT1 tumours) primary melanomas, thicker lesions, benign naevi and melanoma metastases is shown in Table 1 and illustrated in Fig. 1 .
Only four of 76 (5%) primary melanomas were maspin-negative, which is significantly less than the proportion of benign naevi (nine of 13) or melanoma metastases (three of 10) where maspin was not detected (69% and 30%, respectively). In maspin-positive primary lesions, the staining was significantly higher (strongly positive) in thin melanoma lesions (AJCC/UICC pT1 tumours; 18 of 24) compared with thicker lesions (one out of 48). None of the benign naevi or melanoma metastases stained strongly positive for maspin. 
Discussion
The incidence of cutaneous melanoma has increased dramatically in recent decades in Europe, North America and Australasia. Despite extensive efforts to understand the biology of melanoma, therapeutic progress for this tumour type has been limited and new progression and prognostic markers are awaited. It is essential that we understand melanoma progression in more detail in order to be able to develop new therapeutic targets. 24, 25 We show in this study that downregulation of maspin expression can be demonstrated in intermediate thickness and thick melanoma primary lesions compared with thinner lesions. This finding is consistent with other reports, which show a loss of maspin expression to be associated with poor tumour prognosis. 12 -15 Our results suggest that maspin could be involved in the process of local tumour invasion or metastatic spread. While Wada et al. 20 failed to detect maspin immunoreactivity in a series of 40 benign melanocytic naevi, however, we observed maspin staining in our small series of control benign naevi. This new observation also suggests a possible role of maspin in normal physiological processes.
Maspin is a member of the serpin family and is thought to have tumour suppressor activity. 12, 13, 26 Proteases and their inhibitors are known to play an important role in cancer progression and metastasis, which are part of a multi-step process: tumour growth in the primary lesion; invasion of the surrounding vessels; detachment of malignant cells; dissemination through blood or lymphatic vessels; re-adhesion of tumour cells to endothelium; invasion of the surrounding normal tissue; angiogenesis; and secondary tumour growth. 27, 28 Two categories of proteases have been extensively studied in cancer research: serine proteases, including plasminogen activators and their inhibitors Different mechanisms have been advocated to explain the roles of proteinases and proteinase inhibitors in cancer progression, and it has become clear that they could interfere with extracellular matrix turnover, angiogenesis, cellular migration and cytokine production. Maspin has been reported to play a role in cell migration, angiogenesis and apoptosis. 2, 14 Possible molecular targets for maspin are tissue-type plasminogen activator (TPA) and different integrins. 29 Since maspin belongs to the serpin family, its expression is located in the cytoplasmic compartment; we, however, have shown that maspin can also be found in the nucleus. Our findings are in accordance with other studies that also showed nuclear expression of maspin in breast, prostate, and pancreatic tumours. 1, 3, 5, 19 Maspin might have different functions depending on its cellular localization, and this remains to be investigated.
Decreased maspin expression has been explained by epigenetic phenomenon such as aberrant cytosine methylation and heterochromatization of the maspin gene promoter, rather than loss or rearrangement of the gene. 20 Futscher et al. 30 demonstrated that maspin expression in normal cells is regulated by epigenetic modification in a cell type specific way. Maspin-positive cells, including mammary, prostate epithelia and keratinocytes, showed no methylation at the CpG islands of the maspin gene promoter region, while maspin-negative cells, including fibroblasts and lymphocytes, showed methylation of the promoter. 30 In this study we observed that a decrease in maspin expression, as measured by immunohistochemistry, was demonstrated in intermediate and thick primary melanoma lesions. We conclude that a decrease or loss of maspin expression could lead to increased local invasiveness and might contribute to the spread of melanoma cells. Further studies are needed to determine further the biological and clinical implications of the differential expression of this protease inhibitor. 31 
